A Phase 1 interventional study of Eflornithine (Dose Level 1) and Eflornithine (Dose Level 2) in Glioblastoma, IDH-wildtype, Glioblastoma and Glioblastoma Multiforme, sponsored by Orbus Therapeutics, Inc.. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by Orbus Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.
Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 268th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 58 that started in 2023, is one of 481 in phase 1, reaches primary completion later than 60 of the 322 other live ones, and was the 1,142nd registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:
Macarena De La Fuente, MD · Sites in United States
Ages 18+
Alpheus Medical, Inc. · Sites in United States
Ages 18–80
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Inova Health Care Services · Sites in United States
Ages 18–98
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 671 · Phase 2 592 · Phase 3 55 · Phase 4 4
First in 1979; this study’s year is marked. 58 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 66 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 33 across the 1,155 interventional studies, 60 across the 79 observational. Of the 882 that completed or were terminated, 344 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
321 of 1,302 have an industry lead sponsor. The 10 most frequent:
Orbus Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Orbus Therapeutics, Inc. has 1 study filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
105 of the studies in Glioblastoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT03743662Memorial Sloan Kettering Cancer CenterNivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | 2026-11 |
| NCT04574856University of Michigan Rogel Cancer CenterMultiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | 2026-11-19 |
| NCT02704858Neonc Technologies, Inc.Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | 2026-11-30 |
| NCT05781321Mayo ClinicShort Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | 2026-11-30 |
Add all 105 to your calendar (.ics) → With an account.
Among the 1,302 studies in Glioblastoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
This open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose.
Duration of participation will be up to approximately 104 weeks in total per patient.
Screening Period - A maximum screening duration of 4 weeks.
Treatment Period - Up to approximately 104 weeks.
Follow-Up Visit - 4 weeks from last treatment.
Long-term Survival Follow-Up - up to 2 years from last treatment.
A total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the RP2D to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Eflornithine (Dose Level 1) · Drug: Temozolomide
Drug: Eflornithine (Dose Level 2) · Drug: Temozolomide
Drug: Eflornithine (Dose Level -1) · Drug: Temozolomide
Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Also known as: DFMO
Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Also known as: DFMO
Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule
Also known as: DFMO
Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule
Also known as: Temodar, TMZ
Assessment of Dose Limiting Toxicities
Protocol Defined Dose Limiting Toxicities
Time frame: 8 weeks
Incidence of TEAEs All Grades
All Grades
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Grade 3+
Grade 3+
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Serious
Serious
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of TEAEs Leading to Discontinuation
Leading to Discontinuation
Time frame: From enrollment to the end of treatment
Vital Signs (Heart and Respiratory Rate)
Change from Baseline in Heart Rate and Respiratory Rate
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Vital Signs (Blood Pressure)
Change from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests
Lab abnormalities by CTCAE v5.0 Grade
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Overall Survival
Until death or initiation of new anticancer therapy
Time frame: From enrollment to up to 2 years after last dose
Progression Free Survival
Per RANO Criteria as assessed by MRI
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Overall Response Rate
Per RANO Criteria as assessed by MRI
Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment
Pharmacokinetics Cmax
observed maximum concentration
Time frame: Baseline to Steady State (2 weeks)
Pharmacokinetics Cmin
observed minimum concentration
Time frame: Baseline to Steady State (2 weeks)
Pharmacokinetics Tmax
time of observed maximum concentration
Time frame: Baseline to Steady State (2 weeks)
Pharmacokinetics AUCt
area under the concentration-time curve
Time frame: Baseline to Steady State (2 weeks)
Pharmacokinetics lambdaz
elimination rate constant
Time frame: Baseline to Steady State (2 weeks)
Pharmacokinetics t 1/2
elimination half life
Time frame: Baseline to Steady State (2 weeks)
QTcF-Concentration Relationship
Assessment of change in QTcF relative to plasma concentration of eflornithine
Time frame: Baseline to Steady State (2 weeks)
Assessment of QTcF
Change from baseline in QTcF
Time frame: Baseline to Steady State (2 weeks)
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jun 2026, 35 months after the start.
Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 35 months is below that.
Counting every sponsor, half of 322 studies reached it within 44 months; a quarter within 29 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eflornithine
Orbus Therapeutics, Inc.